Natco Pharma and the University of Hyderabad (UoH) have signed an MoU to carry out advance research in the areas of pharmaceutical segment.
The focus areas would be discovery of novel drugs, development of drug delivery systems viz., nano formulations of new chemical entities and biotechnological processes for specific products with potential commercial importance.
The two Hyderabad-based entities will promote cooperation in academic exchange, R & D collaborations, training and research in the areas of biotechnology, pharmacology, toxicology, pharmaceutical technology, and organising of national and international symposia, conferences, specialized exhibitions etc.
The agreement was inked today by Chowdary V Nannapaneni, Chairman and Managing Director of Natco Pharma Ltd. and P Sardar Singh, Registrar of UoH in the presence of Appa Rao Podile, Vice Chancellor & faculty of the School of Life Sciences.
The School has been working with Natco Pharma and in one of the projects has resulted in developing one of the molecules to Phase-II clinical trials for the treatment of chronic myeloid leukaemia. It has a faculty of 55 with 350 PhD and 60 Post Docs and latest research facilities.
The MoU signed for a period of five years will foster the academy-industry interactions by utilising expertise of the faculty and the infrastructure facilities for promoting anti cancer drug discovery research and development at Natco Pharma, said the university press release